

# Concept Life Sciences confirms Scizys' compatibility with automated staining – ready for customer sample testing

**Lumito AB (publ) announces today that the UK-based contract research organisation Concept Life Sciences has completed the first stage of the evaluation of Lumito's product, Scizys Erbium kit and Scizys scanner. The positive outcome marks a significant step forward in bringing Lumito's high-sensitivity tissue analysis solution to the market and is strengthening the position of both companies.**

Lumito's labelling reagent kit (Scizys Erbium kit) has been successfully integrated with a fully automated laboratory staining procedure, a key step towards broader adoption in pharmaceutical and clinical research markets. With a verified protocol for the Leica BOND RX Fully Automated Research Stainer now in place, Concept Life Sciences are initiating testing on customer samples. The initial tests confirm that Lumito's technology delivers high sensitivity and exceptional, clear image quality, without disturbing autofluorescence, reinforcing Scizys' potential for advanced tissue analysis.

"Having an independent partner verify the integration of our Erbium-based reagent kit with automated staining technology is a strong validation. Automated labelling protocols not only reduce manual effort and increase the throughput but also enhance consistency and reproducibility in the tissue analysis process. This makes our solution scalable and attractive for broader use by CROs and partners, accelerating adoption across the market", says Sanna Wallenborg, CEO at Lumito.

"Lumito's Scizys Erbium staining technology has successfully integrated into our automated staining workflows, delivering clear, high-sensitivity tissue images without autofluorescence. This enables faster and more sensitive analysis – bringing real value to our customers in pharmaceutical and clinical research", says Chris Mills, Senior Scientist at Concept Life Sciences.

The evaluation concludes the first stage of the collaboration announced in a press release earlier this year on March 27, which focuses on optimising Scizys for use in Concept Life Sciences' cutting-edge research service.

**For further information, please contact:**

---

Sanna Wallenborg, CEO Lumito  
E-mail: [sw@lumito.se](mailto:sw@lumito.se)  
Ph: +4670-870 01 68

**About Lumito**

Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. [www.lumito.se/en/](http://www.lumito.se/en/)

**About Concept Life Sciences**

Concept Life Sciences is an innovative Contract Research Organization (CRO) dedicated to accelerating drug discovery and development through cutting-edge scientific expertise and state-of-the-art technologies. With a multidisciplinary team specializing in biology, chemistry, ADME/DMPK, and bioanalytics, they provide tailored solutions to pharmaceutical and biotech companies, helping them navigate the complexities of drug discovery from concept to clinic. [www.conceptlifesciences.com](http://www.conceptlifesciences.com)

**Attachments**

[Concept Life Sciences confirms Scizys' compatibility with automated staining – ready for customer sample testing](#)